BioCryst losses soar to $32.7M in 2010, including $9.1M in 4Q

Biocryst Pharmaceuticals (Nasdaq: BCRX) reported a loss of $32.7 million, or 73 cents per share, in 2010, the company reported Thursday.

Boosted by federal support for development of a pandemic flu vaccine, Biocryst reported a $13.5 million loss a year earlier.

In the fourth quarter, the firm reported a loss of $9.1 million, or 20 cents per share. A year earlier, boosted by federal payments for the development of a pandemic vaccine, BioCryst reported a $15.2 million quarterly profit.

The company’s research and development costs climbed to $82.5 million in 2010 from $72.3 million a year earlier. General operating expenses also increased, hitting $14.2 million compared to $11.5 million in 2009.

Revenues fell to $63.5 million from $74.6 million in 2009.

For the full earnings report and a recap of 2010, read here.

Get the latest news alerts: Follow WRAL Tech Wire at Twitter.